Article

Wavefront-optimized LASIK achieves equal outcomes to wavefront-guided LASIK, study finds

Three- and 6-month clinical results comparing wavefront-optimized and wavefront-guided treatments with the Allegretto Wave excimer laser (WaveLight Laser Technologie AG) showed that both treatment approaches achieved nearly identical visual outcomes postoperatively, and neither treatment induced higher-order aberrations. WaveLight outlined the results of the study in a prepared statement as presented by Bill Bond, MD, of Bond Eye Associates, Pekin, IL.

Chicago-Three- and 6-month clinical results comparing wavefront-optimized and wavefront-guided treatments with the Allegretto Wave excimer laser (WaveLight Laser Technologie AG) showed that both treatment approaches achieved nearly identical visual outcomes postoperatively, and neither treatment induced higher-order aberrations. WaveLight outlined the results of the study in a prepared statement as presented by Bill Bond, MD, of Bond Eye Associates, Pekin, IL.

The prospective randomized, controlled multicenter study was initiated in September 2004 to evaluate the safety and effectiveness of wavefront-guided treatments (incorporating the Allegro wavefront analyzer) and to compare results with wavefront-optimized (standard LASIK) with the Allegretto Wave, according to WaveLight.

Myopic patients up to 7 D with up to 3 D of astigmatism were eligible to participate in the study. Approximately 82% of all patients reported postoperative visual acuity better or equal to preoperative best-corrected visual acuity and 55% of patients gained one or more lines of vision. No loss in contrast sensitivity was observed with either platform, the company said.

In addition, 81% of eyes presented with ≤ 0.3 µm of preoperative higher-order aberrations (HOAs) and achieved equivalent outcomes with either wavefront-guided or wavefront-optimized treatments. For the remaining 19% of patients presenting with significant HOAs (> 0.3 µm), HOAs were reduced slightly more with wavefront-guided treatments than with wavefront-optimized treatments. On average, neither platform was shown to induce HOAs following treatment.

In other news, the company announced the closure of the 100th Allegretto Wave excimer laser system sale in the United States.

“Reaching this milestone in less than 2 years represents WaveLight’s growing role in the U.S. refractive market,” said Wade Tetsuka, president of WaveLight Inc. “With each laser installation, WaveLight brings increasing value to the physician’s practice by introducing a new standard of care in laser vision correction.”

For more information visit WaveLight Technologie AG at Booth 3250.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.